𝔖 Bobbio Scriptorium
✦   LIBER   ✦

782 CHRONIC HEPATITIS C GENOTYPE 4: EFFICACY AND SAFETY OF THE TREATMENT WITH PEGINTERFERON ALFA-2A PLUS RIBAVIRIN

✍ Scribed by M. Diago; J. Boadas; R. Planas; R. Sola; J.A. del Olmo; J. Crespo; J.C. Erdozaín; M.D. Anton

Book ID
117376708
Publisher
Elsevier Science
Year
2008
Tongue
English
Weight
60 KB
Volume
48
Category
Article
ISSN
0168-8278

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of insulin resistance with met
Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin
✍ Manuel Romero-Gómez; Moisés Diago; Raúl J. Andrade; José L. Calleja; Javier Salm 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 309 KB 👁 1 views

Insulin resistance affects sustained virological response (SVR) in chronic hepatitis C. To know whether adding metformin to standard antiviral treatment improves SVR, we conducted a prospective, multicentered, randomized, double-blinded, placebo-controlled trial in 19 Spanish hospitals, including 12

Peginterferon alfa-2b plus ribavirin tre
Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C
✍ Stefan Wirth; Heidrun Pieper-Boustani; Thomas Lang; Antje Ballauff; Ulrike Kullm 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB 👁 2 views

Peginterferon plus ribavirin is standard therapy for adults with chronic hepatitis C. As no data are available for children, the aim of the study was to evaluate the efficacy and tolerability of peginterferon alfa-2b in combination with ribavirin in chronically infected children. Genotypes, alanine

Efficacy and safety of peginterferon alf
Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis
✍ Savino Bruno; Mitchell L. Shiffman; Stuart K. Roberts; Edward J. Gane; Diethelm 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 500 KB 👁 1 views

The objective of this study is to determine the efficacy and safety of peginterferon alfa-2a (40 KD)/ribavirin in patients with advanced fibrosis. Data from 341 genotype 1/4 patients (99 with bridging fibrosis/cirrhosis) treated for 48 weeks and 1547 genotype 2/3 patients (380 with bridging fibrosis